Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2969793 | The Journal of Heart and Lung Transplantation | 2015 | 7 Pages |
Abstract
Reducing anti-thrombotic therapies in response to bleeding among HMII patients was achievable but may be associated with a higher risk for device thrombosis. Furthermore, despite an RT strategy, bleeding often will persist in those prone to such events.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jason N. MD, MHS, Robert M. MD, Ranjit MD, Antone MD, Kartik PhD, Faouzi PhD, David J. PhD, Ulrich P. MD, on behalf of the TRACE study on behalf of the TRACE study,